Overview
WuXi Biologics (WuXi Bio), a leading global CRDMO, and Medigene AG, an immuno-oncology platform company, announced that they have entered into a three-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of difficult-to-treat tumours. The collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and WuXi Biologics’ unique anti-CD3 mAb, its industry leading TCE platform and proprietary bispecific antibody platform WuXiBody.
Words from the CEO: WuXi Biologics
Dr. Chris Chen, CEO of WuXi Biologics, commented, “We are excited to partner with Medigene, a leader in TCR generation and characterization. This collaboration will further enhance our research service capabilities in our CRDMO business model and underscore our commitment to enabling global partners to speed up their novel therapy discovery and development with our leading technologies and reliable services. I believe the partnership will be ultimately translated into better treatments for cancer patients worldwide.”
Statement from the CEO: Medigene
- We are confident that Medigene’s known capabilities in generating potential best-in-class 3S TCRs for TCR-T cell therapies can also be applied to non-cellular modalities,” said Selwyn Ho, CEO of Medigene.
- As such, we are delighted to be able to partner with WuXi Biologics with their validated anti-CD3 mAb, and its industry leading TCE platform and WuXiBody to support our strategy to apply Medigene’s TCRs into new modalities, such as TCR-TCEs for use in patients where additional value can be created beyond TCR-T therapies, for patients and our shareholders.
About WuXiBody
- WuXiBody is a leading proprietary bispecific antibody platform developed by WuXi Biologics.
- It can effectively break through the discovery and CMC barriers for the development of many bispecific antibodies with high expression yield, high stability, good solubility, and easy purification to homogeneity, expedite the process by 6-18 months and significantly reduce manufacturing costs, limitations still faced by many other current bispecific platforms.
- WuXiBody platform enables almost any mAb sequence pairs to be assembled into bispecific constructs, which are expected to have low immunogenicity risk and longer in vivo half-life.
- WuXiBody platform also has a unique structural flexibility, which makes it convenient to build various formats with different combinations of valencies (1+1, 1+2, 2+2) to meet the requirements of different target biology.
About WuXi Biologics
WuXi Biologics is a leading global contract research, development and manufacturing organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
About Medigene AG
Medigene AG is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer.
